(Q37524006)

20 August 2017

1 reference

title

Diabetes medications and body weight (English)

1 reference

20 August 2017

Joanna Mitri

1

1 reference

PubMed ID

19538102

20 August 2017

Osama Hamdy

series ordinal

2

1 reference

PubMed ID

19538102

20 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Drug Safety

20 August 2017

1 reference

20 August 2017

8

1 reference

20 August 2017

5

1 reference

20 August 2017

573-584

1 reference

Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome

20 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Overweight, obesity, and blood pressure: the effects of modest weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effect of laparoscopic Roux-en-Y gastric bypass surgery on hemoglobin A1c levels in diabetic patients: a matched-cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Prevention of weight gain in type 2 diabetes requiring insulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Repaglinide versus glyburide: a one-year comparison trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effects of combined insulin-sulfonylurea therapy in type II patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Adiponectin: A novel adipokine linking adipocytes and vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Rosiglitazone RECORD study: glucose control outcomes at 18 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Biphasic insulin aspart 30: literature review of adverse events associated with treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Miglitol: assessment of its role in the treatment of patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Potential causes of weight gain in type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Weight changes following the initiation of new anti-hyperglycaemic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Weight gain during insulin therapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Tissue selectivity of insulin detemir action in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Insulin glulisine provides improved glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Amylin, food intake, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903081725

10.1517/14740330903081725

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19538102